Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Suzhou Shengdiya Biomedicine
Suzhou, Jiangsu, Chinahrssd.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AiRuiKa (camrelizumab) is a marketed anti-PD-1 monoclonal antibody for multiple oncology indications; NDA submissions and approvals in China for metastatic solid tumors and NSCLC; global multicenter trials ongoing.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibody
- Industry
- Pharma
02
Partnerships
Parent resources with Hengrui MedicinePotential partnerships via Hengrui for global development, but not specifically listed
Beyond the preview
Go deeper on Suzhou Shengdiya Biomedicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Shengdiya Biomedicine.